Molecular signatures in the diagnosis and management of diffuse large B-cell lymphoma

Research output: Contribution to journalReview article

12 Scopus citations

Abstract

Purpose of Review: This review summarizes recent data on the relevance of molecular subtypes of diffuse large B-cell lymphoma to clinical management and the potential to use subtyping to direct therapy. Recent Findings: Gene expression profiling and immunohistochemistry can distinguish between diffuse large B-cell lymphomas arising from germinal center-derived B-cells (GCB type) or activated B-cells (ABC type) with a high degree of concordance. This biologic distinction is highly relevant clinically. The ABC type is associated with a poor prognosis and is characterized biologically by constitutive activation of the NF-κB pathway and chronic activation of the B-cell receptor pathway, both of which confer an antiapoptotic phenotype and chemoresistance. Emerging preclinical and clinical data suggest that these pathways can be targeted specifically in ABC-type disease. New molecular techniques may allow further refinement of this approach. Summary: Recent data support the concept that molecular subtyping of diffuse large B-cell lymphoma is clinically relevant and likely to be incorporated into diagnostic and therapeutic algorithms. The availability of widely applicable and reproducible techniques for determining molecular subtype will be essential.

Original languageEnglish (US)
Pages (from-to)288-292
Number of pages5
JournalCurrent opinion in hematology
Volume18
Issue number4
DOIs
StatePublished - Jul 1 2011

    Fingerprint

Keywords

  • diffuse large B-cell lymphoma
  • gene expression profiles
  • immunohistochemistry
  • targeted therapies

ASJC Scopus subject areas

  • Hematology

Cite this